Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $896.1 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 35.54% year-over-year to $896.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.2 billion (up 33.43% YoY) and the FY2025 annual result came in at $763.6 million, up 31.54% from the prior year.
• Liabilities and Shareholders Equity advanced to $896.1 million in Q2 2026, from $825.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $896.1 million in Q2 2026 to a low of $210.6 million in Q2 2022.
• A 5-year average of $553.0 million and a median of $534.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 25.77% — and 2023, when it jumped 130.0%.
• Tracing KNSA's Liabilities and Shareholders Equity over 5 years: stood at $459.7 million in 2022, then gained by 14.5% to $526.3 million in 2023, then advanced by 10.3% to $580.6 million in 2024, then surged by 31.54% to $763.6 million in 2025, then grew by 17.35% to $896.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $896.1 million (Q2 2026), $825.3 million (Q1 2026), and $763.6 million (Q4 2025), per Business Quant data.